卡瑞利珠单抗-话题@MedSci

#卡瑞利珠单抗#

14篇内容 | 4036人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2172152, encodeId=edbf21e2152fd, content=<a href='/topic/show?id=2a4d391818a' target=_blank style='color:#2F92EE;'>#吡咯替尼#</a>联合<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>和化疗一线治疗<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>晚期<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>具有令人惊喜的疗效结果。, objectTitle=疾病控制率100%！《柳叶刀》子刊：胃癌一线治疗有望迎来重磅疗法！, objectType=article, longId=801776, objectId=c363801e764a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/type2diabetes-s2-stomach-and-pancreas.jpg, objectUrl=/article/show_article.do?id=c363801e764a, replyNumber=0, likeNumber=93, createdTime=2023-11-30, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=c363801e764a, moduleTitle=疾病控制率100%！《柳叶刀》子刊：胃癌一线治疗有望迎来重磅疗法！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c363801e764a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088998, encodeId=f284208899844, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a><a href='/topic/show?id=699f104e68e9' target=_blank style='color:#2F92EE;'>#超适应证#</a>用药情况分析, objectTitle=某院卡瑞利珠单抗超适应证用药情况分析, objectType=guider, longId=19012, objectId=7b6b31c00263e3d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=7b6b31c00263e3d9, replyNumber=0, likeNumber=105, createdTime=2022-09-19, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b6b31c00263e3d9, moduleTitle=某院卡瑞利珠单抗超适应证用药情况分析, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=7b6b31c00263e3d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1218140, encodeId=38d3121814064, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>对<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a>, objectTitle=Clin Cancer Res：法米替尼、卡瑞利珠单抗和nab-紫杉醇联合治疗晚期三阴性乳腺癌, objectType=article, longId=301566, objectId=a12430156640, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022323/1648049526637_2467676.JPG, objectUrl=/article/show_article.do?id=a12430156640, replyNumber=0, likeNumber=134, createdTime=2022-05-09, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a12430156640, moduleTitle=Clin Cancer Res：法米替尼、卡瑞利珠单抗和nab-紫杉醇联合治疗晚期三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a12430156640)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1218139, encodeId=18c812181390d, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>在<a href='/topic/show?id=ccf410109188' target=_blank style='color:#2F92EE;'>#食管癌#</a>, objectTitle=J Immunother Cancer：卡瑞利珠单抗+化疗作为局部晚期食管癌术前辅助治疗的疗效和安全性, objectType=article, longId=301810, objectId=b131301810c5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022327/1648386345263_2467676.JPG, objectUrl=/article/show_article.do?id=b131301810c5, replyNumber=0, likeNumber=150, createdTime=2022-05-09, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b131301810c5, moduleTitle=J Immunother Cancer：卡瑞利珠单抗+化疗作为局部晚期食管癌术前辅助治疗的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b131301810c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1218138, encodeId=4e8a12181386c, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>, objectTitle=国产免疫治疗药卡瑞利珠单抗适应症和不良反应大盘点！, objectType=article, longId=725912, objectId=130de259127f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220430/1651326906855_5486984.png, objectUrl=/article/show_article.do?id=130de259127f, replyNumber=0, likeNumber=101, createdTime=2022-05-09, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=130de259127f, moduleTitle=国产免疫治疗药卡瑞利珠单抗适应症和不良反应大盘点！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=130de259127f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1184282, encodeId=c5da11842828b, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>联合<a href='/topic/show?id=196b9e808ed' target=_blank style='color:#2F92EE;'>#阿帕替尼#</a>二线治疗晚期<a href='/topic/show?id=f02010113143' target=_blank style='color:#2F92EE;'>#食管鳞癌#</a>疗效显著, objectTitle=Lancet Gastroenterol Hepatol：郑大一附院王峰教授CAP 02研究显示卡瑞利珠单抗联合阿帕替尼二线治疗晚期食管鳞癌疗效显著, objectType=article, longId=293995, objectId=58f82939954d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022114/1642144428855_1611618.jpg, objectUrl=/article/show_article.do?id=58f82939954d, replyNumber=0, likeNumber=163, createdTime=2022-01-14, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58f82939954d, moduleTitle=Lancet Gastroenterol Hepatol：郑大一附院王峰教授CAP 02研究显示卡瑞利珠单抗联合阿帕替尼二线治疗晚期食管鳞癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58f82939954d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1015862, encodeId=5d2e101586237, content=<a href='/topic/show?id=196b9e808ed' target=_blank style='color:#2F92EE;'>#阿帕替尼#</a>与<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>联合，毒性可能过大，还是T+A方案可能更好！除非阿帕替尼用小剂量！！, objectTitle=J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果, objectType=article, longId=208916, objectId=dc73208916ac, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021323/1616492833763_2110107.PNG, objectUrl=/article/show_article.do?id=dc73208916ac, replyNumber=0, likeNumber=171, createdTime=2021-09-08, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc73208916ac, moduleTitle=J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc73208916ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=909651, encodeId=24129096511a, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>, objectTitle=阿帕替尼+卡瑞利珠单抗联合出击，为NSCLC患者带来新希望, objectType=article, longId=168141, objectId=9b1716814124, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201906/20190611211023855.jpg, objectUrl=/article/show_article.do?id=9b1716814124, replyNumber=0, likeNumber=149, createdTime=2020-12-20, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b1716814124, moduleTitle=阿帕替尼+卡瑞利珠单抗联合出击，为NSCLC患者带来新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b1716814124)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=909650, encodeId=e1e89096508f, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>, objectTitle=Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）, objectType=article, longId=194143, objectId=2d2a194143a2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20200513/46e94c0c53ee42eda7414e18d6d0b6ee.jpg, objectUrl=/article/show_article.do?id=2d2a194143a2, replyNumber=0, likeNumber=168, createdTime=2020-12-20, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d2a194143a2, moduleTitle=Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d2a194143a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=909649, encodeId=a13a9096497f, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>, objectTitle=AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究, objectType=article, longId=193104, objectId=5d7319310411, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20200420/94a119d961644e548119175cf8fd19f4.jpg, objectUrl=/article/show_article.do?id=5d7319310411, replyNumber=0, likeNumber=169, createdTime=2020-12-20, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d7319310411, moduleTitle=AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d7319310411)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=909648, encodeId=d87690964818, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>, objectTitle=J Clin Oncol：未来可期| 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌！, objectType=article, longId=202292, objectId=ae1420229214, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20201019/1603095070707_2110107.PNG, objectUrl=/article/show_article.do?id=ae1420229214, replyNumber=0, likeNumber=164, createdTime=2020-12-20, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae1420229214, moduleTitle=J Clin Oncol：未来可期| 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae1420229214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=909647, encodeId=9f5d90964ec8, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>, objectTitle=卡瑞利珠单抗创造肺癌最长总生存期, objectType=article, longId=204726, objectId=e8bb204e26f4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20201220/1608454899251_5268530.png, objectUrl=/article/show_article.do?id=e8bb204e26f4, replyNumber=0, likeNumber=151, createdTime=2020-12-20, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8bb204e26f4, moduleTitle=卡瑞利珠单抗创造肺癌最长总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8bb204e26f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

卡瑞利珠单抗

2020-05-29

侠胆医心 (审核中...)

前往app查看评论内容

#吡咯替尼#联合#卡瑞利珠单抗#和化疗一线治疗#HER2阳性#晚期#胃癌#具有令人惊喜的疗效结果。

疾病控制率100%！《柳叶刀》子刊：胃癌一线治疗有望迎来重磅疗法！

2023-11-30发表于威斯康星

小小医者 (审核中...)

前往app查看评论内容

#卡瑞利珠单抗##超适应证#用药情况分析

某院卡瑞利珠单抗超适应证用药情况分析

2022-09-19

病毒猎手 (审核中...)

前往app查看评论内容

#卡瑞利珠单抗#对#三阴性乳腺癌#

Clin Cancer Res：法米替尼、卡瑞利珠单抗和nab-紫杉醇联合治疗晚期三阴性乳腺癌

2022-05-09

病毒猎手 (审核中...)

前往app查看评论内容

#卡瑞利珠单抗#在#食管癌#

J Immunother Cancer：卡瑞利珠单抗+化疗作为局部晚期食管癌术前辅助治疗的疗效和安全性

2022-05-09

病毒猎手 (审核中...)

前往app查看评论内容

#卡瑞利珠单抗#

国产免疫治疗药卡瑞利珠单抗适应症和不良反应大盘点！

2022-05-09

病毒猎手 (审核中...)

前往app查看评论内容

#卡瑞利珠单抗#联合#阿帕替尼#二线治疗晚期#食管鳞癌#疗效显著

Lancet Gastroenterol Hepatol：郑大一附院王峰教授CAP 02研究显示卡瑞利珠单抗联合阿帕替尼二线治疗晚期食管鳞癌疗效显著

2022-01-14

病毒猎手 (审核中...)

前往app查看评论内容

#阿帕替尼#与#卡瑞利珠单抗#联合，毒性可能过大，还是T+A方案可能更好！除非阿帕替尼用小剂量！！

J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果

2021-09-08

lovetcm (审核中...)

前往app查看评论内容

#卡瑞利珠单抗#

阿帕替尼+卡瑞利珠单抗联合出击，为NSCLC患者带来新希望

2020-12-20

lovetcm (审核中...)

前往app查看评论内容

#卡瑞利珠单抗#

Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）

2020-12-20

lovetcm (审核中...)

前往app查看评论内容

#卡瑞利珠单抗#

AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究

2020-12-20

lovetcm (审核中...)

前往app查看评论内容

#卡瑞利珠单抗#

J Clin Oncol：未来可期| 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌！

2020-12-20

lovetcm (审核中...)

前往app查看评论内容

#卡瑞利珠单抗#

卡瑞利珠单抗创造肺癌最长总生存期

2020-12-20

科室
- - 订阅+
  - 更多科室
工具
服务